Fig. 4. Centi-C10 antibody properties and discovery process. (a) Centi-C10 potency quantified by neutralization assays of spike-pseudotyped lentivirus (mean ± SD, assayed in duplicate). (b) Antibodies capable of binding the SARS-CoV-2 receptor binding domain (RBD), and thus blocking the binding of the virus to ACE2 receptors on human cells, were discovered by multiple rounds of panning and selection from an ScFV phage library built from a SARS-CoV-1-binding parental antibody.
